SVB Leerink started coverage on shares of XOMA (NASDAQ:XOMA – Get Free Report) in a research note issued to investors on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $40.00 price target on the biotechnology company’s stock. SVB Leerink’s price target suggests a potential upside of 57.85% from the company’s current price.
Separately, HC Wainwright restated a “buy” rating and issued a $74.00 price target on shares of XOMA in a research report on Thursday, April 25th.
View Our Latest Analysis on XOMA
XOMA Price Performance
XOMA (NASDAQ:XOMA – Get Free Report) last posted its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The firm had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.01 million. On average, analysts expect that XOMA will post -1.73 earnings per share for the current fiscal year.
Institutional Investors Weigh In On XOMA
A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC increased its holdings in XOMA Co. (NASDAQ:XOMA – Free Report) by 25.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 436,602 shares of the biotechnology company’s stock after acquiring an additional 87,203 shares during the period. XOMA makes up about 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th largest holding. Stonepine Capital Management LLC owned approximately 3.80% of XOMA worth $6,152,000 as of its most recent SEC filing. 95.92% of the stock is currently owned by hedge funds and other institutional investors.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Read More
- Five stocks we like better than XOMA
- Earnings Per Share Calculator: How to Calculate EPS
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Evaluate a Stock Before BuyingÂ
- Hilton Demonstrates Asset Light is Right for Investors
- How to Start Investing in Real Estate
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.